Lifecore Biomedical Inc

LFCR remains in a clear Stage 4 decline with a series of lower highs and lower lows confirmed by the down-sloping EMAs and 200DMA. The active Bearish Pivot Point pattern signals failure of upside control and continued structural repair to the downside. Mean Reversion is not eligible, so the medium-term tradable side stays bearish. Price is currently near the 9EMA and below the 20EMA/50DMA without a decisive rejection or exhaustion signal, offering no clear immediate sell trigger. Execution should be deferred, waiting for rallies into the declining EMA zone and prior resistance for disciplined sell entries.

• ↑High profitability (score 0.85) and Q1 gross profit of $5.4 M
• ↑Ten late-stage programs expected FDA approval by 2028
• ↓Q1 net loss $16.2 M and negative earnings yield signal profitability issues